Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Libaoduo
- Development stage
- Unknown
- Lead developer
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Libaoduo is a pegylated liposomal formulation of doxorubicin hydrochloride developed by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical. It is an anthracycline antineoplastic agent primarily indicated for the treatment of advanced ovarian cancer in patients who have failed first-line platinum-based chemotherapy, as well as for AIDS-related Kaposi's sarcoma and multiple myeloma. The drug works by intercalating between DNA base pairs and inhibiting topoisomerase II, which disrupts DNA replication and RNA synthesis in rapidly dividing cancer cells. The liposomal delivery system significantly alters the pharmacokinetics of doxorubicin, allowing for enhanced accumulation in tumor tissues through the enhanced permeability and retention (EPR) effect while reducing systemic toxicity, particularly the risk of dose-limiting cardiotoxicity associated with conventional doxorubicin formulations.
- Brand names
- Libaoduo
- Other names
- Doxorubicin hydrochloride liposome injectionPegylated liposomal doxorubicinPLD
02
Targets
DNATOP2B (DNA topoisomerase II beta)TOP2A (DNA topoisomerase II)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on Libaoduo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Libaoduo.